INAVA

Across TCGA pan-cancer cohorts, INAVA mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated INAVA data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher INAVA mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated INAVA expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where INAVA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.293	0.905	.038	3	view →
HNSC	OS	Median	All	0.917	0.991	.043	3	view →
LUAD	OS	Quartile	All	1.000	0.929	.028	2	view →
LSCC	OS	Median	All	0.806	0.947	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

INAVA–PDAC (OS)

Open the PDAC breakdown →